Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
3Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Elite Pharmaceuticals, Inc. (ELTP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
2Distinct source URLs
12High confidence
0.867Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Elite Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
BUREL-PHARMACEUTICALS-INC
BUREL-PHARMACEUTICALS-INC
90%
the Company entered into a license, manufacturing and supply agreement with Prasco, LLC and its affiliate Burel Pharmaceuticals, Inc.
NOSTRUM-LABORATORIES-INC
NOSTRUM-LABORATORIES-INC
90%
the Company entered into an asset purchase agreement with Nostrum Laboratories Inc.
PRASCO-LLC
PRASCO-LLC
90%
the Company entered into a license, manufacturing and supply agreement with Prasco, LLC and its affiliate Burel
SUPPLIER
SUPPLIER
90%
Three suppliers accounted for approximately 71 % of the Company's purchases of raw materials for the nine months ended December 31, 2024.
LANNETT-COMPANY-INC
LANNETT-COMPANY-INC
85%
The Company has entered into two separate license, supply and distribution agreements with Lannett Company Inc.
PRAXGEN-PHARMACEUTICALS-LLC
PRAXGEN-PHARMACEUTICALS-LLC
80%
The product is jointly owned by Elite and Praxgen Pharmaceuticals LLC
Elite Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
CUSTOMER
CUSTOMER
90%
Two customers accounted for approximately 76 % of the Company's accounts receivable as of December 31, 2024.
EPIC-PHARMA-LLC
EPIC-PHARMA-LLC
90%
we entered into a license, manufacturing and supply agreement with Epic Pharma LLC to market the two Elite generic products described below in the United States
CAPITAL-RESOURCES-CAPITAL-RESOURCES
CAPITAL-RESOURCES-CAPITAL-RESOURCES
62%
the nine months ended December 31, 2025 as compared to the comparable period of the prior year The increase in interest income is primarily due to higher interest rates being earned on the Company’s …
Elite Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ELTP-DEBT-9270
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-03-31.
ELTP-DEBT-9269
Warrants outstanding: 0.1521
90%
xbrl warrant detail from xbrl 2023-12-31.
ELTP-DEBT
Debt stack $2.4M
90%
Market cache reports total debt of $2.4M.
Elite Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Elite Pharmaceuticals, Inc..
Elite Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
ELTP-OWNER-KELLEHER-FINANCIAL-ADVISORS
KELLEHER FINANCIAL ADVISORS
90%
13F overlay lists KELLEHER FINANCIAL ADVISORS as top holder; 1 tracked holders.
Elite Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
